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ABSTRACT
LIFE AFTER ADHESION: L-SELECTIN THROUGHOUT THE T CELL
LIFESPAN
by
Abner Fernandez
The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Dr. Douglas Steeber, Ph.D.
Lymphocytes require antigenic encounter to activate and proliferate,
eventually clearing the source of antigenic challenge. The peripheral lymph
nodes (PLN) are the primary sites of antigenic encounter and thus the ability of
lymphocytes to migrate to this tissue is a requirement for mounting effective
immune responses. The process of lymphocyte migration to the PLN is known as
the “adhesion cascade”. Specifically, lymphocytes are captured from the blood
through the adhesion molecule, L-selectin, followed by CC chemokine receptor 7
(CCR7)-mediated

integrin

activation,

which

ultimately

results

in

cell

transmigration into the PLN. Because the PLN is the site where antigenic
encounter is most likely, we hypothesized that migration may induce proproliferative signaling, mediated by L-selectin and conducted through CCR7. To
study the potential “priming” effects of adhesion to antigen-mediated lymphocyte
proliferation, spleen and PLN lymphocytes were subjected to in vitro
transmigration and proliferation assays. Subsequently, multi-color flow cytometry
analysis was used to examine treatment effects on the T cell population. Results
showed that lymphocyte proliferation was significantly increased when L-selectin
and CCR7 were activated simultaneously, compared to CCR7 activation alone.
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Specifically, bulk tissue populations, as well as the CD4+ and CD8+ T cell subsets
showed enhanced proliferation from both spleen and PLN sources at early and
late time points. Additionally, to discern whether this enhanced proliferation may
be a by-product of decreased apoptosis, an apoptosis assay was also performed
at the same time points. Interestingly, L-selectin engagement resulted in
protection from apoptosis for all T cell populations 72 hour following activation.
However, this protective effect was not observed at the 36 hour time point. Taken
together, these results suggest a role for L-selectin in enhancing T cell
proliferation, at least in part, through an anti-apoptotic effect. This research will
add to a better understanding of the regulation of lymphocyte proliferation and
increase our knowledge of L-selectin signaling function.
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Chapter 1: General Introduction
Migration and recirculation of lymphocytes are important prerequisites for
generating an effective immune response. These processes are accomplished
through the adhesion cascade in conjunction with chemoattractive factors. The
role of L-selectin in lymphocyte migration and recirculation is well documented
(1-4). However, its subsequent role late in the adhesion cascade remains
unclear. In the peripheral lymph nodes (PLN), circulation of lymphocytes that
have not encountered antigen (naïve cells) is primarily mediated by L-selectin
and CCR7 (5). The PLN is where lymphocytes encounter their cognate antigen
leading to activation and cell proliferation. The manipulation of CCR7 and Lselectin is therefore an attractive avenue for either augmenting or attenuating the
lymphocyte response. Limiting the responding cell population in states of
pathological hyperactive immune response, as seen in autoimmune disorders,
may alleviate the negative manifestations of such disorders. In contrast, a robust
response may be desired in other cases such as infections and vaccinations.
Recent results from our lab suggest that L-selectin engagement along with
subsequent ligand (secondary lymphoid tissue chemokine, SLC, CCL21) binding
of CCR7 enhances chemotaxis (6), and decreases apoptosis (7) L-selectin also
contributes to the effectiveness of 2-integrin- mediated lymphocytic arrest (8-10).
In neutrophils, L-selectin engagement also causes increased secretion of
products that degrade pathogens, thus contributing to the effectiveness of the
responses (11). Therefore, mounting evidence suggests that the initial step in
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leukocyte migration involving L-selectin, contributes to the effectiveness of other
subsequent steps such as transmigration and terminal effector response.
1. T cells
T cells are white blood cells that arise from hematopoietic stem cells from
red bone marrow (Figure 1). They are named T lymphocytes due to their
maturation in the thymus (12). They are a subset of lymphocytes that express the
T cell receptor (TCR, Figure 2)-a multi-molecular complex that recognizes
specific peptide antigens normally presented by a self-cell expressing a marker
known as the major histocompatibility complex (MHC, 13). Thus, T cells require a
cognate antigen with a corresponding MHC to mount an effective or any
response. T cells are divided into CD8+ or CD4+ T cells. T cells that express the
CD4 co-receptor on their membrane are classified as helper T cells (T h cells).
Their primary role is to coordinate the immune response, thus helping other
immune cells in antigenic clearance and the maintenance of homeostasis (14).
CD4+ T cells recognize antigens on antigen presenting cells (APC) which
express the MHC-class II molecule. CD4+ T cells are primarily responsible for the
clearance of pathogens of extracellular origin. The TCR of CD4+ T cells can
recognize longer peptide antigens compared to the TCR of CD8+ T cells (15).
CD8+ T cells on the other hand recognize peptide antigen along with the
MHC-class I molecule which is a self-marker expressed by virtually all nucleated
cells. CD8+ T cells are called cytotoxic T cells (Tc cells) due to their ability to
secrete factors that result in cell death. CD8+ T cells are primarily responsible for
the destruction of virally-infected or defective self-cells (tumors) and therefore
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respond to intracellular challenges. CD8+ T cells are also responsive to CD4+ T
cell-mediated co-stimulation. The biggest driver of CD8+ T cell proliferation is
interleukin-2 (IL-2) secreted primarily by CD4+ T cells (16).
The TCR expressed by the majority of T cells is a dimer of  and  chains
that have arisen independently from each other through genetic rearrangement
of their membrane distal variable regions. This provides for high variability and
accounts for the unimaginable repertoire of variable regions specific for a
multitude of peptide antigens. The TCR dimer is surrounded by 5 invariant chains
of the CD3 complex: 2 , 1 , 1  and 2  chains. The CD3 molecules contain
conserved

cytoplasmic

regions

called

Immunoreceptor-Tyrosine-based-

Activation-Motifs (ITAM) which are rich in potential phosphorylation residues.
Interestingly, due to its short cytoplasmic tail, the TCR cannot generate
intracellular signaling on its own and must therefore signal by coopting
neighboring molecules such as the CD3 molecule. The co-receptor CD4 or CD8
is also expressed, dependent on the T cell subset ,and interacts with MHC-class
II or MHC-class I molecules, respectively. Finally, a CD28/CTLA-4 (Cytotoxic TLymphocyte Antigen-4) dimer is also considered part of the TCR complex. CTLA4 is up-regulated in activated cells. CD28 stimulation results in an “on” signal
while CTLA-4 stimulation results in an “off” signal (17).
T cells react to antigens presented by other cells called APCs in a
stepwise fashion. A cognate peptide for the TCR must be detected along with
two

other

signals

for

proper

T

cell

activation

to

occur.

First,

the

TCR+peptide/MHC contact must be accompanied by a CD4+MHC-class II or
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CD8+MHC-class I interaction; second, a co-stimulatory molecule, specifically the
CTLA-4/CD28 dimer must also be stimulated by their respective ligands on the
APC. Failure for any of these interactions to happen almost simultaneously
results in T cells that are anergic and thus unable to activate (18). This anergy
can still be overcome if the incoming signal is of high duration and quality (19).
Once a T cell is stimulated properly, a kinase normally associated with the
cytoplasmic tail of CD4 or CD8, light chain kinase (Lck), phosphorylates the
ITAM’s of the  chains of CD3. The phosphorylated  chains in turn recruit zeta
associated protein of 70 kDa (ZAP-70), which due to its close proximity to the
inner leaflet of the cell membrane can now interact with scaffolding proteins such
as linker of activated T cells (LAT) and the SH2 domain-containing leukocyte
protein of 76 kDa (SLP-76). The final products of TCR signaling are the
transcriptional up-regulation of proteins required for cell activation and
proliferation and down-regulation of genes that are in opposition. Additionally,
effector molecules to clear the immunogenic challenge are also transcribed,
which include but are not limited to: IL-2 (20) and interferon- (21) for CD4+ T
cells, or granzyme and perforin for CD8+ T cells (22). The signaling pathways
that are normally utilized involve the Ras (rat sarcoma family of proteins, 23),
PLC (phospholipase-C, 24), and NFB (nuclear factor kappa B proteins, 25).
The result of TCR activation is the clonal expansion of that specific T cell
lineage. In the best case scenario, the cause of antigenic challenge is eventually
eliminated and the response of other T cell populations eventually downregulates the effector response (26). T cells that are products of antigen-induced
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proliferation and have survived the initial response are called memory T cells (T m
cells). This memory pool is yet divided into at least two other subsets: effector
memory T cells (Tem) which are sequestered in the tissue in which they are
activated in, and central memory T cells (T cm) which can still recirculate between
the blood and the periphery (27). Their interaction with antigen in subsequent
encounters creates a rapid and heightened response, resulting in the faster
elimination of the immune challenge.
2. T cell migration
Lymphocytes require antigenic encounter to respond effectively, and
antigenic encounter requires that these cells circulate throughout the whole
organism. In the blood, the hemodynamic flow provides for maximal interaction
between circulating lymphocytes and possible antigens. However, in areas of the
body where flow dynamics is not dominant, such as in the PLN or cutaneous
tissue, discrete and overlapping steps that capture lymphocytes from the blood
must be established (28). Lymphocyte recirculation into the parenchyma is
mediated

by

several

overlapping

steps

with

corresponding

receptor

engagements, intracellular responses, and ultimately a cellular physical
response. In a homeostatic state, immune cell circulation in the PLN is mediated
sequentially (Figure 3). First, the adhesion molecule L-selectin interacts with its
ligands expressed on the endothelium (collectively called peripheral node
adressins, PNADs) to arrest high velocity immune cells in the bloodstream. The
cells, now decreased in their velocity, have the opportunity for the CCR7 receptor
to interact with its ligand, CCL21. CCL21 is a soluble chemokine generated by
local lymphoid tissue, thus its other name, secondary lymphoid tissue chemokine
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(SLC). CCL21, although soluble, is sequestered on the vascular endothelium by
glycosylaminoglycans (GAG’s, 29). The CCR7+CCL21 interaction triggers the
change in conformation of 2-integrins (lymphocyte function associated antigen1, LFA-1), another class of adhesion molecule expressed on the lymphocyte
(30). The change in conformation from a low affinity to a high affinity
conformation of the integrin allows it to interact with its ligand, intercellular
adhesion molecule-1 (ICAM-1), expressed on the endothelium to firmly arrest the
cells. Finally, the lymphocytes transmigrate through the blood vessels into the
PLN through processes such as cystoskeletal remodeling and basement
membrane degradation (31). Once in the lymph node, lymphocytes may
encounter their cognate antigen (activation). This interaction along with costimulatory signals, results in clonal expansion (proliferation) and terminal
differentiation, into either effector cells that mediate antigenic clearance (CD8+ T
cells) or response-coordinating cells (CD4+ T cells).
3. L-selectin
L-selectin belongs to the selectin family of adhesion molecules and is
expressed by all leukocytes (32). The E/P/L-selectins are multi-domain
transmembrane proteins that have a ligand binding lectin domain, an epidermal
growth factor-like domain, and short consensus repeat (SCR) domains (Figure
4). The differences between the 3 selectin molecules rest on two factors, cell
expression patterns and the number of SCR domains. E-selectin is expressed by
inflamed endothelium and P-selectin is expressed by activated platelets and
inflamed endothelium. Both E-and P-selectin have a varied SCR number
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between species, normally ranging from 4-9, whereas L-selectin’s SCR is
conserved between species at 2. Interestingly, all selectins seems to share
ligands perhaps due to the common post-translational modifications required of
their respective ligands. Naïve or circulating T cells have been shown to express
higher levels of L-selectin compared to B cells (4). Because of migration
differences in the spleen’s open circulation, and the PLN (separated from the
blood by high endothelial venules (HEV)), the majority of cells in the PLN express
high levels of L-selectin (33). Furthermore, naïve T cells express the highest
levels of L-selectin, because activated T cells are normally sequestered in their
activation sites to create an environment conducive to antigenic clearance, and
thus are not required to recirculate (34) .
L-selectin can be cleaved upon engagement at a membrane proximal region
by a metalloproteinase, tumor necrosis factor -converting enzyme (TACE or
ADAM17, 35). This cleavage results in a soluble form of the molecule, sLselectin, that can be detected in the plasma. It has also been shown that sLselectin can still bind to its ligands and perhaps serve to saturate L-selectin
ligands on the endothelium not actively participating in cell-to-cell interactions
(36). Interestingly, L-selectin-mediated tethering which normally happens
between lymphocytes and the endothelium can also occur between leukocytes.
This phenomenon of “secondary tethering” may help recruit more leukocytes to
the endothelium, especially when the endothelium is inflamed (37).
The ligands specific to L-selectin are varied and widespread among a variety
of tissues and cells, especially in HEV of lymph nodes (31). The conserved
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ligand structure is rich in posttranslational addition of modified carbohydrates,
and so far 9 ligands that bind to L-selectin with varying affinities have been
identified. There is a consensus that the molecule sialyl Lewis x (sLex), a
tetrasaccharide, can bind to all 3 selectins (38). However, this seems to stem
from a sulfated modification in sLex. Thus, structures that are sulfated,
fucosylated and sialylated seem to be preferred L-selectin ligands.
The intracellular domain of L-selectin is normally associated with ezrinradixin-moesin (ERM) and calmodulin (CaM) molecules that serve as a scaffold
for spanning adjacent L-selectin molecules (39). The tail is also associated with
-actinin which binds L-selectin to the actin cytoskeleton. This putative binding is
proposed to orient L-selectin into a conformation that restricts access of TACE to
the membrane proximal cleavage region. Once L-selectin binds to ligand, the
ERM scaffold dissociates, leading to L-selectin cleavage and clustering of the
cytoplasmic

tail.

Clustering

of

L-selectin

upon

engagement

promotes

downstream signaling effects such as oxidative burst, and an increase in kinase
activity (10, 40-41). This suggests that L-selectin although a canonical adhesion
molecule, may play a role in other pathways not restricted to adhesion.
4. CCR7 and Secondary Lymphoid Tissue Chemokine (SLC)
Chemokines and their receptors are classified based on the position of the N
terminus conserved cysteine residues (42). Chemokine receptors are serpentine
transmembrane receptors that are often called G-protein coupled receptors due
to their putative signaling mechanism (43). These receptors are normally
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associated intracellullarly with a heterotrimeric G protein that dissociates upon
ligand binding and results in subsequent activation of downstream signals.
CCR7 (Figure 5) is a chemokine receptor that is involved in homeostatic
recirculation of naïve lymphocytes and is highly specific for two ligands, CCL19
(ELC) and CCL21 (SLC) (44). The former is primarily produced in secondary
lymphoid tissues, and serves as a chemoattractive factor for recirculating
lymphocytes (45-46). The CCR7 and SLC/ELC interaction is known to involve
GAGs. GAGs serve as a scaffold upon which soluble SLC can bind (47). The
downstream signaling invoked upon ligand binding has been shown to involve
Ca+2 release mediated by CaM and tyrosine kinase activity (48). These signals
converge downstream to facilitate nuclear translocation of NFB, among many
other factors, resulting in enhanced transcription of a multitude of factors that
enhance chemotaxis through cytoskeletal remodeling and cell polarization (49).
Interestingly, the current body of knowledge also points to chemokine-driven
enhanced effector effects. Chemokines and their receptors have been shown to
serve a role in T cell development (50-51). Specifically for CCR7, it has been
shown that intrathymic development of T cells is impaired in the absence of
CCR7 (52). Furthermore, effector phenotypes such as the ability to lyse cells and
to effectively proliferate can also be enhanced in the presence of CCR7 (53).
Thus, CCR7 has been shown to have post-adhesive effects, which are more
established than for L-selectin.
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5. Lymphocyte surface receptor architecture and relationships
The cell membranes are very crowded places. It must be understood that
membrane receptors are in close proximity with each other and impact the fluidity
of the membrane ultrastructure (54). This is more so in cells that specialize in
signaling such as a T cell. If we consider the number of clusters of differentiation
(CD) antigens alone, one can only imagine the number of receptors on the T cell
surface (55). Additionally, most of these receptors are present in high copy
numbers, thus, creating a higher density of membrane proteins. The effect of
receptors in close proximity to each other implies that they exert pressures and
influences on each other. The crowding effect alone implies that a group of
receptors must be down-regulated in order for another to be overexpressed. This
may be the reason why cells constantly change their receptor repertoire,
dependent on temporal and spatial contexts (56-58).
In the context of the TCR, CCR7 and L-selectin molecules, a direct
association between the three of them is yet un-established. However, in regards
to L-selectin and CCR7, we already alluded to their proposed close association.
Previous studies have suggested that L-selectin activation enhances SLC
induced chemotaxis (6). However, the Subramanian paper is the first paper to
show such a relationship between L-selectin and CCR7 (6). Additionally, Lselectin has also been shown to decrease apoptotic rates in transmigrating cells
when the L-selectin molecule is previously activated (7). Additionally, the same
report indicates an upregulation of the active monomer of NFB, p65, when cells
that are transmigrated in the presence of SLC are previously exposed to an L-
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selectin activating antibody (7). Taken together, L-selectin activation prior to
transmigration to SLC, may increase levels of signaling molecules that serve a
role in proliferation and apoptosis.
In regards to receptor relationships in our context, association between
the TCR and CCR7 is much more established. In a paper by Schaueble (59), it
was shown that TCR-induced activation enhanced short term migration of
peripheral blood mononuclear cells (PBMC). Another paper by Gollmer (60) also
showed that SLC, a ligand for CCR7, can also contribute to CD4 co-receptor
stimulation. Taken together, one can surmise that a relationship between these
three molecules may exist.

6. Hypothesis
Based on the background information presented above, we propose that a
relationship between L-selectin, CCR7 and TCR exists. We hypothesize that Lselectin due to its increasing contributions to events far removed from initial
tethering can also affect TCR-mediated proliferation, transduced through CCR7.
Because of the role of L-selectin in moving lymphocytes from the sterile blood
environment to the antigen rich parenchyma, we propose that L-selectin “primes”
cells before antigenic encounter and thus hypothesize:
1. That L-selectin can increase TCR-induced proliferation.
2. That L-selectin exerts an anti-apoptotic effect on T cells
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3. That L-selectin-mediated effects will be more pronounced in CD8+ T cells, due
to a higher density of L-selectin in this subset, and in the PLN, due to the higher
number of L-selectin positive cells in this tissue.

All
nucleated
cells

Antigen
Presenting
Cell
MHC-II
Antigenic
peptide

MHC-I
TCR
CD4

CD8

CD3

+

+

Figure 1. T lymphocytes. T (matures in the Thymus) lymphocytes consist of two major subsets: CD4 and CD8 cells. Both types have a common
CD3 marker but possess the distinct co-receptors: CD4 or CD8. The TCR itself has variable regions specific to distinct antigenic peptide
+
arrangements. Thus, T cells do not react to the same antigen. CD4 T cells respond to peptides presented by antigen presenting cells (APC):
+
dendritic cells primarily and phagocytic cells to a lesser extent. APCs display MHC-class II molecules which must be recognized by the CD4 T cell
+

+

for a response. CD8 T cells respond to all nucleated cells (including APCs) but requires MHC-class I on the presenting cell for a response. CD4
T cells are coordinating cells of the immune system, signaling other immune cells to increase or decrease their respective responses relative to
+
the challenge, thus they are called helper T cells. CD8 T cells act by directly killing cells presenting the proper antigen and MHC molecule, thus
they are called cytotoxic T cells.
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Figure 2. T cell receptor complex. The T cell receptor complex consists of multiple molecules. It utilizes the TCR dimer (most commonly an  and
 chain) and the CD4/8 co-receptor to respond to antigen. The TCR dimer consists of two independent variable region (V) and two constant
regions (C). The V region is responsible for antigen specificity. Once an antigen complementary to the V region is encountered and presented by a
self-cell displaying the proper MHC, a response is initiated by the CD4/8 molecule’s light chain kinase (Lck) which induces phosphorylation of the 
chains of CD3. This in turn recruits other signaling proteins to perpetuate kinase cascades: NFAT, NFB, MAPK, as the 3 most important kinase
pathways. The antigen presentation to the TCR must be accompanied by a co-stimulatory signal which is transduced through the CD28+CTLA-4
dimer. Co-stimulatory failure results in cells that are anergic.
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Figure 3. Adhesion Cascade. Events that follow are typical at the interface between the blood and the vascular endothelium of the PLN. A
lymphocyte is slowed down by L-selectin interacting with its ligand expressed on the vascular endothelium, resulting in lymphocyte rolling (1). The
rolling cell’s chemokine receptor can now interact with its ligand that is sequestered on the endothelium by glycosylaminoglycans (2). This result in
activation and a conformation change in the integrin receptor into an active form (3), which results in integrin-mediated firm arrest (4). Cells can
then transmigrate into the underlying tissue (5).
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Lectin Domain

Cytoplasmic Region

EGF-like Domain

SCR Region
Cleavage Site
Transmembrane region
Actin

Figure 4. Structure of human L-selectin. L-selectin consists of 4 extracellular regions along with a short (17 amino acids) cytoplasmic tail. The
activation domain which is farthest from the cell is the lectin domain, followed by an epidermal growth factor (EGF)-like domain. It has 2 short
consensus repeats (SCR), which is numerically conserved among species. A cleavage site that becomes accessible for a metalloproteinase
during activation is present in the membrane proximal region. The short cytoplasmic domain which anchors the molecule to the actin cytoskeleton
has putative binding sites for calmodulin and -actinin. Protein Kinase C is known to phosphorylate the two serine residues (circled). Figure
courtesy of Steeber et al., 2007 (31).
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Figure 5. CC chemokine receptor 7 (CCR7) and its ligands. CCR7 is a chemokine receptor expressed by dendritic cells and T and B cells. The
two known ligands are CCL19 (also known as ELC) and CCL21 (also known as SLC). The CCR7/SLC combination induces chemotaxis of
lymphocytes into the parenchyma of the PLN, in cooperation with selectins and integrins. CCR7, as are all other chemokine receptors, is a Gprotein coupled receptor. Thus signaling involving G and G molecules is activated during receptor-ligand interaction.
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Chapter 2: Characterization of T cell proliferation with L-selectin and CCR7
activation
1. Research design
As previously covered in the introduction, lymphocytes need to be able to
recirculate between the blood and lymphoid tissues to maximize the surveillance
capacity of these cells and thus optimize conditions for mounting the adaptive
immune response. L-selectin plays a crucial step in minimizing cell velocity in the
blood-lymph node boundary. This “speed bump” effect increases cell contact with
the vascular endothelium which polarizes the cell and induces its transmigration.
As evident in the above description and from the adhesion cascade review in the
introduction, L-selectin is not a stand-alone molecule, as compared to the TCR
complex. Its effects towards the succeeding events after transmigration of the
cell requires transduction via other molecules involved in the same pathway.
Although direct studies of L-selectin contributions to vast arrays of T cell
processes have been performed (61-62), most have centered on migratory
capacity and none have dissected its contribution to TCR-induced proliferation;
an event far removed from the initial L-selectin-mediated tethering and rolling
steps.
The direct activation of L-selectin and subsequent measurements of TCRindependent proliferation is possible. However, we surmised that the signaling
effects of L-selectin may be weak and transitory (63-64) and thus may not truly
mirror its signaling effects in vivo. Furthermore, direct measurement of
proliferation after L-selectin activation is not physiologically relevant, because
most T cell activation occurs after the cell has migrated from the blood into the
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lymph nodes, where the vast array of antigen presenting cells can directly
interact with the transmigrated T cell (65-66). It is important to note that this
mechanism of T cell activation is also possible in the spleen (67-68). However,
the spleen is a predominantly B cell organ (69), where humoral immunity is more
involved. Because T cell activation may come from both spleen and lymph
nodes, regardless of the T cell proportion, both tissue T cell residents were
isolated and analyzed for L-selectin-induced proliferative effects. To correct for
the possible weak effect of L-selectin-mediated signaling which may be masked
by “all or none” events such as TCR-induced proliferation; we coopted a
molecule that serves with L-selectin in vivo. To this end we selected another
molecule that has been shown to act with L-selectin in the adhesion pathway;
CCR7 (70-71). In vivo, SLC is present on the surface of HEV in lymph nodes and
thus its receptor, CCR7, is immediately activated after L-selectin-induced rolling
(72). It has also been shown that activation of chemokine receptors on
leukocytes can result in phosphorylation of serine residues in the cytoplasmic tail
of L-selectin (73). A connection between L-selectin and CCR7 was recently
shown by our lab with the demonstration of increased lymphocyte chemotaxis to
SLC following L-selectin activation (6). CCR7 in this regard may serve as a
molecular bridge between the initial L-selectin step and the terminal step of TCRinduced proliferation. To test this idea, a in vitro assay was developed that
mimics T cell transmigration and eventual TCR-induced activation and
proliferation. This assay was performed by activating L-selectin via a specific
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antibody, followed by chemotaxis in a transwell system in the presence of SLC
and finally a terminal assay of anti-TCR-induced activation and proliferation.
To measure levels of activation and proliferation empirically, resulting cell
populations may be assessed with an activity assay such as the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide

(MTT)

assay.

The

shortcoming of such an assay is that MTT reduction into the colored formazan
product requires an active NADH dehydrogenase (74). NADH dehydrogenase is
a mitochondrion-restricted enzyme (75-77). Mitochondrial enzymatic activity may
be down regulated in cells that have been exposed to sustained proliferative
signals and cell-to-cell inhibition due to volume restrictions and hypoxic
conditions (78-79). Furthermore, the use of an organic hydrophobic substance
such as dimethyl sulfoxide (DMSO) to solubilize the crystals is problematic,
because hydrophobic substances, especially DMSO readily diffuses into the
vapor phase. The MTT assay also requires a response/cell standard. Because
this assay is based on enzymatic activity, cell populations from the same
conditions must be used for analysis and as standards. Analyzing subset effects
also requires homogenous cell purification prior to the assay, which is time and
resource intensive. Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE)
is an intracellular fluorescent stain (80). In the CFDA-SE form it is nonfluorescent and readily passes through the hydrophobic cell membrane (81).
Once it is in the cytoplasm, intracellular esterases cleave it into the
carboxyfluorescein succinimidyl ester (CFSE) form. CFSE is fluorescent with an
excitation/emission signature of 492nm/517nm. Furthermore, CFSE is not readily
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permeable and can be covalently linked to protein residues in the inner leaflet of
the cell membrane. Thus in its CFSE form it is restricted to the intracellular
compartment. Another advantage of CFSE is that only viable cells can convert
and retain it. The intracellular esterases responsible for its conversion are also
not mitochondrion restricted. Furthermore, cell division results in a stoichiometric
halving of the CFSE signal (82). Thus, each progeny population will have a
CFSE fluorescence intensity signature of approximately half of the previous
generation. However, optimal concentrations of CFSE must be empirically
determined because excessive amounts, although non-toxic, will render the cells
anergic (83).
The monoclonal antibody (mAb) against the lectin domain of L-selectin,
LAM1-116, was generated previously and has been shown to induce homotypic
adhesion between lymphocytes in vitro (10). Interestingly another L-selectin
antibody generated from the same fusion, LAM1-101, recognizes the EGF/SCR
region of the molecule and has been shown to induce no phenotypic effects on
cells. In relation to this thesis, we utilized LAM1-116 as an activating anti-Lselectin antibody and LAM1-101 as a negative control antibody. The superiority
of using two antibodies generated against the same molecule, but specific to two
different domains with corresponding phenotypic effects, has huge advantages.
Using isotypic antibodies that can bind to the same molecule with approximately
equal affinity is superior to assays utilizing non-specific mouse antibodies, most
notably in cases where non-specific mouse IgG is used. Alternatively activation
of L-selectin with phorbol myristate acetate (PMA) could have been used but its
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relevance in vivo would have been lost, since the mechanism of PMA activation
is via an inside-out signaling mechanism utilizing protein kinase C (PKC, 84),
which is atypical of L-selectin function in the context of migration. A different
approach for activating L-selectin would have been to utilize its natural ligands.
However, a preferred or dominant L-selectin ligand has still not been identified
(32). Instead, L-selectin is known to bind to a vast array of ligands, including
ligands that have been shown to bind to other adhesion molecules, such as Pselectin glycoprotein ligand-1 (PSGL-1), a ligand that can bind to all selectin
molecules (85). Some reports have also shown that L-selectin can be activated
by binding molecules known to have been incorporated post-translationally, such
as sulfatides or glycoproteins. However, these modifications are not unique to Lselectin ligands and their activaty may require other molecules besides L-selectin
such as sulfatide receptors.
A transwell or transmigration system mimics the interface between blood
and the parenchymal tissues such as the PLN (86). The system that we used has
an upper and lower chamber, corresponding to the blood and parenchyma
respectively. The bottom chamber can be loaded with chemokines or any other
putative chemoattractive substance, which can be separated from the lower
chamber with polycarbonate membranes with varying pore sizes. The pore size
is important because transmigration into the periphery requires T cell polarization
and cytoskeletal rearrangement (87). If a smaller pore size compared to the
cellular diameter of the population of interest is used, only cells that actively
transmigrate through cellular polarization and rearrangement can be found in the
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lower chamber after a pre-determined amount of time. The time utilized for this
transmigration/chemotaxis assay must be determined empirically because the
chemokine or any chemoattractive substance will readily diffuse between
chambers, ultimately resulting in equilibrium where no chemical gradient is
present and thus resulting in cell inertia or worse, reverse transmigration, which
may happen in cases where the chemical has partial solubility and less density
than the media. The limitation of the transmigration assay is that the number of
cells that transmigrate dictates any subsequent assays. In our case, the volume
of the chambers is quite small and thus the numbers of cells available for the
subsequent proliferation assay is limited. Another possible challenge is that the
transmigrated cell population may have a preponderance to favor a specific T cell
subset. If this is the case, the proliferation analysis will already have an
established bias towards the dominant transmigrating subset. To correct for this
population issue and still maintain research integrity of paired tests, the assays
were performed one tissue at a time and multiple wells were utilized per
treatment. Briefly, there were 4 transmigration treatments: 1) untreated cells, 2)
cells transmigrated in the presence of SLC, 3) cells previously treated with
activating LAM1-116 mAb and transmigrated in the presence of SLC, and 4) cells
previously treated with control LAM1-101 mAb and transmigrated to SLC. Wells
coinciding with the same treatment were pooled to generate enough cells for the
next assay. Subset analysis by flow cytometry was also performed after pooling
to guard against any subset bias.
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The cells from the transmigration assay were subsequently exposed to a
TCR-induced proliferation assay using monoclonal antibodies against two transmembrane proteins, the TCR-associated epsilon subunit of the CD3 complex and
the co-stimulatory molecule, CD28. Cross linking of surface proteins, especially
those with signaling capabilities such as CD3 and CD28, provokes downstream
signaling that induces proliferation (88-89).

Both antibodies were needed

because ligation of CD3 alone only invokes the initial activation of T cells (90-91)
whereas co-ligation of CD28 is needed for sustained cell proliferation (92).
Because TCR signaling puts T cells under extreme duress, time points were
empirically determined to assess the peak levels of proliferation.
Cell analysis was performed using a flow cytometer. A flow cytometer has
a distinct advantage of analyzing high numbers of cells in multiple populations in
minimal amounts of time. Antibodies with conjugated fluorescence molecules or
fluorescent dyes specific to the cell of interest can be detected via a flow
cytometer. An important property of flow cytometry that allows for detection of
labeled cells one at a time is called hydrodynamic focusing. Hydrodynamic
focusing is similar to liquid chromatography albeit without a stationary phase.
Two layers of fluid diameters are aligned; the outer layer called the sheath
volume pushes the inner fluid diameter layer which makes up the sample. Cell
suspensions are pushed through the flow cytometer system via differing
velocities of a buffering liquid, hence the word “flow”. The sheath diameter of fluid
pushing the cells is a product of its velocity. Slower flow is a product of a smaller
sheath fluid diameter, hence a larger sample fluid diameter. When the sheath
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diameter increases, the sample fluid diameter decreases resulting in greater
force and greater sample velocity. Due to the small sheath diameter, the inner
cell suspension can be optimized to a diameter slightly larger than the cell of
interest. This results in one cell per unit volume. The fluorescently labeled cells,
one at a time are then passed through an excitation source and their resulting
emission, which is of a low magnitude is amplified via a series of photomultiplier
tubes. This system does not just detect cell surface proteins but with a cell
permeabilization step can also detect intracellular molecules.

2. Materials and Methods
i. Animals and Tissues
C57BL/6 mice (Jackson Labs, Bar Harbor, ME) were raised in pathogen-free
conditions with unrestricted access to food and water. Mice were used at 2-4
months of age. Cells isolated from the spleen, and inguinal and axillary lymph
nodes were exclusively used for all experiments. All tissues were dissected
under aseptic conditions. Mice were sacrificed via CO2 inhalation. All animal
procedures were approved by the Institutional Animal Care and Use Committee
of the University of Wisconsin-Milwaukee.
ii. Lymphocyte Isolation
Single-cell suspensions of mouse splenocytes were prepared by mechanical
homogenization of the spleen while in suspension with 0.1 M phosphate buffered
saline (PBS), and filtration of debris through a 120 m pore sized nylon mesh
(Elko Filtering, Miami FL). Red blood cells were lysed in a KHCO3-buffered 0.15
M NH4Cl solution. The resulting red blood cell-free cell solution was filtered,
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washed and centrifuged twice in PBS. All cells were re-suspended in Dulbecco’s
PBS (DPBS, Life Technologies, Carlsbad CA) unless otherwise stated.
Lymphocytes from bilateral inguinal and axillary lymph nodes were similarly
prepared with the exception of the red blood cell lysis step. Cell counts were
determined using a 0.04% trypan blue exclusion assay with a hemacytometer.
Dead cells have permeable membranes and thus will present with a blue
cytoplasm which can be excluded from the resulting cell count.
iii. CFSE Staining
Lymphocytes (10 x 106 cells/mL) from the spleen and lymph nodes that were
isolated as previously described, were incubated for 15 minutes at 37°C in 0.25
M of CFDA-SE (Molecular Probes, Carlsbad CA) in pre-warmed DPBS, with
regular mixing.

The required cell and CFSE concentrations were previously

determined empirically. The concentrations used gave high CFSE Mean
Fluorescence Intensity (MFI) of equal to or greater than 10 3, yet still provided
responsive reporter cells. Resulting suspensions were washed twice with DPBS
supplemented with 10% Heat-Inactivated Fetal Bovine Serum (HI-FBS, Life
Technologies). HI-FBS was needed to quench excess CFSE, minimizing its antiproliferative effects. The cells were then re-suspended in RPMI-1640 medium
(Life Technologies) supplemented with 10% HI-FBS, and allowed to equilibrate at
a 37°C water bath for 30 minutes. The previous 30 minute step at that
temperature allows the cells to cleave the diacetate moiety of CFDA-SE and
covalently

link

CFSE

intracellularly,

allowing

for

staining

stability

and

reproducibility. All antibodies used in the subsequent experiments were
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purchased from BD Pharmingen (San Jose, CA) unless otherwise stated. Flow
cytometric subset analysis for L-selectin expression was then undertaken, using
anti-mouse CD4 (Clone:RM4-5) conjugated to Phycoerythrin (PE), anti-mouse
CD8 (Clone:53-6.7) conjugated to AlexaFluor 647, and biotin conjugated LAM1116 monoclonal antibody against L-selectin, which was revealed with a PE-Cy5.5
fluorophore conjugated to avidin. Briefly, LAM1-116 mAb and LAM1-101 mAb
were isolated from the ascites fluid of RAG-1-knockout mice injected in the
peritoneum with the hybridomas for each antibody. The antibodies were isolated
and concentrated from ascites by NH4SO4 precipitation, followed by extensive
dialysis with column buffer (0.1 M NaC2H3O2, pH 5). The antibodies were then
purified by protein G affinity chromatography and released with elution buffer (0.1
M glycine-HCl, pH 2.8). The eluted antibody fractions were neutralized by 1M
Tris, pH 9.0. The neutralized chromatography fractions were pooled and after
extensive 0.1 M PBS dialysis, the antibody purity was confirmed by reducing
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE).
Aliquots of the purified mAbs were divided into fractions and stored at -20°C until
use. Biotinylated LAM1-116 was prepared by mixing 0.15 mg of EZ-Link®-NHSLC-Biotin (Thermo Scientific, Waltham MA) per 1 mg of purified antibody, for one
hour at room temperature. Free biotin was removed from antibodies by extensive
dialysis with 0.1 M PBS. The antibody concentrations of the pooled fractions
were determined using a NanoDrop® scanning spectrophotometer (Thermo
Scientific) at OD280. The resulting solutions were re-suspended in 0.1 M PBS and
stored at 4°C until use.
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L-selectin staining of CFSE-treated cells was done 12 hours post CFSE
staining. L-selectin staining was undertaken at the 12 hour time point because
initial CFSE fluorescence interfered with any flow cytometric analysis by bleeding
into multiple fluorescent channels that was not correctable by instrument
compensation. To ensure that L-selectin was not prematurely shed by CFSElabeled cells during the 12 hour waiting period, all samples were stored at 4°C
until L-selectin staining was performed. Optimum antibody concentrations were
determined empirically through fluorescence titration studies. All working
antibody solutions were diluted in PBS+ 2% NHS. All antibody staining was
carried out on ice for 30 minutes. Non-specific mouse IgG mAbs conjugated to
the same fluorophores (Southern Biotech, Birmingham, AL) were utilized as nonspecific isotypic controls in all cases. Unbound antibodies were removed prior to
flow analysis with a terminal wash step using PBS supplemented with 2% normal
horse serum (Thermo Scientific). All flow cytometric acquisitions were performed
using a BD FACSCalibur instrument (BD Biosciences, San Jose, CA). Cells were
gated on the population that showed forward and side light scatter properties of
mononuclear cells. At least 5000 events were collected for each sample. All
subsequent data were analyzed with CellQuestTM Pro (BD Biosciences) software.
iv. Chemotaxis Assay
CFSE-labeled lymphocytes (1 x 106 cells/mL), re-suspended in RPMI1640 supplemented with 0.1% bovine serum albumin (DNAse/RNAse/Protease
free BSA (Fraction V), Fisher Scientific, Waltham MA) were then subjected to a
chemotaxis assay, using the 48 well Neuroprobe System (Neuroprobe Inc.,

29
Gaithersburg, MD). The lower chamber was loaded with 50 L of RPMI1640+0.1% BSA, with or without 500 ng/mL of SLC (Peprotech, Rocky Hill, NJ).
The SLC concentration used has been shown to induce chemotaxis of at least
50% of input T cells (6). The whole apparatus was then assembled with a 5 m
pore size polycarbonate membrane separating the upper and lower chambers.
The upper chamber was then loaded with 3 treatment groups of cells (5 x 104
cells/50 L/well). The different treatments were: cells in media alone, cells
treated with 10 g/mL of LAM1-116 mAb, and cells treated with 10 g/mL of
LAM1-101 mAb. The appropriate antibodies were added to the cells prior to
chemotaxis. Cells were then allowed to chemotax in a humidified, 37°C, 5% CO2
incubator (Thermo Scientific) for one hour. The chemotaxed cells from the same
treatment were pooled and adjusted to a final cell concentration of 2.5 x 105
cells/mL, in RPMI-1640 medium supplemented with: 0.1% BSA, 100 U/mL
penicillin, 100 g/mL streptomycin, 2 mM L-glutamine and 55 M mercaptoethanol

(all

supplements

were

from

Life

Technologies).

-

mercaptoethanol was not initially used due to the possibility of disulfide bond
reduction in the presence of this chemical. SLC and L-selectin have multiple
disulfide linkages that may be reduced and thus may result in the loss of
functional

secondary

structure

of

these

two

molecules.

However,

-

mercaptoethanol was ultimately used after LAM1-116 mAb and SLC treatment to
prevent the cellular aggregation inherent in long-term subculturing of primary
cells. Prior to incubation in the presence of anti-TCR antibodies, lymphocyte
subset analysis via flow cytometry was then performed using PE-conjugated anti-
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mouse CD4 and AlexaFluor 647-conjugated anti-mouse CD8 mAbs. This
analysis was performed prior to the cells being used for the subsequent assays.
v. Proliferation Assay
The previously pooled chemotaxed cells were then subjected to a TCRinduced proliferation assay. A sterile 96 well round-bottom assay plate (Thermo
Scientific) was coated with low endotoxin/NaN3-free grade anti-mouse CD3
(Clone:145-2C11) and anti-mouse CD28 (Clone:37.51) mAbs, both used at 2
g/30 L diluted in 37°C DPBS. The maximum amount of antibody that can bind
to round-bottom wells has been shown to be approximately 3 g/well (93). After
90 minutes in a 37°C, 5% CO2 incubator, unbound antibodies were removed by
washing the wells with 4°C DPBS. Cells from the previous assay were then
added to each well at a density of 5 x 104 cells/200 L, and were allowed to
proliferate in a 37°C, 5% CO2 incubator. Cells were collected at the 36 and 72
hour time points and were subsequently analyzed for proliferation and apoptosis.
Proliferation effects per subset were analyzed singly using anti-mouse CD4 and
anti-mouse CD8 mAbs both conjugated to AlexaFluor 647 and in some cases,
double staining with the same Alexa Fluor conjugated anti-mouse CD8 but with
an anti-mouse CD4 conjugated to PE. Cells that displayed increasing side and
forward light scatter, a property of proliferating lymphoblasts, were included in the
live cell gating. Histograms of proliferating cells were compared to a
corresponding CFSE-stained cell sample without TCR-induced proliferation. A
similarly prepared CFSE sample must be utilized because the fluorescence
intensity of CFSE exhibits some time-dependent decay. Autofluorescence
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correction for negative cells was done using corresponding samples not labeled
with CFSE. Thus, the area of the histogram flanked by the non-proliferated
sample and the unlabeled cell sample were considered to be the proliferating
population. The percentages of the proliferating population of the SLC-treated
samples were compared to the sample exposed to media alone.
vi. Data Analysis
After analyzing the raw data for homogeneity of variance with the Bartlett
test and normality with a Q-Q line plot, deviations were detected that proved the
raw data unusable. To correct for these departures from normality and variance
all data were normalized as follow:
%Proliferation Enhancement = (frequency of cells proliferating in the
treated sample/frequency of proliferating cells in the untreated sample) *100
In some cases the frequency of each cell division was also determined.
Manual gates were drawn to peaks corresponding to the area flanked by the
negative and positive CFSE sample. Each subsequent peak had to display
relative fluorescence intensity approximately half of its parent population to be
considered for analysis.
Transformed data were subjected to normality and variance tests, through
Q-Q line plot and Bartlett tests, respectively. No significant departures were
noted or the residuals of the outliers did not impact the outcome of the factors.
Data were then analyzed with one-way ANOVA. If data sets showed significant
variance (p < 0.05), further analysis between groups was performed using the
Tukey Honestly Significant Difference (HSD) test. A P value of less than 0.05
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was considered significant. Pearson correlation was also performed between
Proliferation versus % L-selectin positive cells. All summary data are displayed
with standard error from the mean (SEM) bars. All data analysis was performed
using R 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria).
3. Results
i. Data transformation to correct for statistical bias in raw data from proliferation
studies.
Cells labeled with CFSE and subjected to the transmigration and
proliferation assays were analyzed by flow cytometry. Raw data that was
collected provided a spread that affected data analysis. In the bulk lymphocytic
proliferation assays at the 36 hour time point for the spleen, the numbers that
corresponded to TCR-induced proliferating cells for the CFSE-labeled sample
untreated with SLC or mAb, ranged from 38.7% to 94.36%. This was an
important data spread because the most responsive population treated with SLC
and LAM1-116 simultaneously, also had a big data spread of 48.3% to 98%.
Using a Q-Q plot to determine normality, outliers that impacted the outcome of
the dependent factors were detected. Furthermore, the Bartlett test for
homoscedasticity also yielded departures from variances that were not a product
of normal distribution. In other instances, where data were normally distributed
and homogenous variances were established, the results yielded a P value of
less than 0.05. However, upon closer examination using the post hoc Tukey HSD
test, the significant finding was the result of the negative sample exhibiting lower
proliferation than the treated samples, with no variances between SLC-treated
samples, which rendered our data set differences statistically insignificant. To
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eliminate the departures from normality and homoscedasticity, we transformed
the data sets by comparing all effects to the proliferated but untreated control. As
such, for proliferation, the equation Treatment (SLC, SLC+LAM1-116, and
SLC+LAM1-101)/Control * 100, was used to generate a proliferation index.
Numbers lower than 100% indicate a lower proliferative effect than the control
and numbers greater than 100% indicate effects higher than the control. The
added benefit of this transformation is that the comparisons between samples
are now restricted to 3 samples treated with SLC, narrowing the dependent
variable to L-selectin activation alone. This comparison is utilized for the
remainder of these studies, unless otherwise stated.
ii. Spleen and PLN lymphocytes treated with SLC and LAM1-116 mAb have
increased proliferation at 36 and 72 hours post-TCR stimulation
To mimic in vivo conditions, we utilized mAbs to CD3 and CD28 to create
a condition, parallel to that encountered by T cells during MHC-restricted
antigenic challenge. As expected, all samples showed enhanced proliferation
over the control, likely as a product of SLC treatment (Figure 6). In all cases, SLC
treated samples pre-treated with the L-selectin activating LAM1-116 mAb
showed the greatest enhancement in proliferation (Figure 6 C and G). In the 36
hour spleen sample, the variance between the 3 treatment group samples
compared to the control was significant at P=0.04 (n=10). Interestingly, Tukey’s
HSD test tended towards a significant difference between the SLC+LAM1-116
mAb treated sample versus the SLC treated sample with a P=0.06 (n=10). This
was the same in comparing the LAM1-116 mAb treated sample to the LAM1-101
mAb treated sample with a P=0.09 (n=10). In the PLN sample at the same period
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of 36 hours, the variance was significant at P=0.01 (n=9) with Tukey’s HSD test
showing P=0.01 (n=9) and P=0.04 (n=9) for the LAM1-116 mAb treated sample
compared to SLC alone and the LAM1-101 mAb treated sample, respectively.
Visually analyzing the histograms also showed a discernible increase in the late
cell division population ( by the number of peaks, and the height of the terminal
peak) of the LAM1-116 mAb-treated samples as compared to other samples, in
both the spleen and PLN. We expected proliferation effects to be higher in the
PLN, because this secondary lymphoid organ is T cell rich compared to the
spleen, and T cells as a population have higher frequencies of L-selectin positive
cells. During the early post-stimulation period of 36 hours, this was the case with
proliferation enhancement in the PLN ranging from 115%-134% as compared to
the range in the spleen of 105%-116% (Figure 7).
Interestingly, at 72 hours post-TCR stimulation, treatment groups showed
a general decrease in proliferation enhancement (Figure 8). The decrease in
proliferation of the 72 hour samples does not seem to be a product of time
sensitization but rather a by-product of samples reaching or approaching
asymptotic growth at the later times post-TCR stimulation, indicating all cell
populations have reached close to maximal divisions (Figure 8). This seems to
be a shortcoming of our data transformation which we will address later.
At the 72 hours post-TCR stimulation time point, both the spleen and the
PLN showed an almost equal level of enhanced proliferation with ranges of
108%-117% and 107%-120%, respectively. The ANOVA test showed significant
variances for both spleen and PLN at P=0.015 (n=7) and P=0.016 (n=6),
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respectively (Figure 9). However, regardless of the decreased proliferative
enhancement effect of SLC and LAM1-116 mAb treatment at 72 hours poststimulation, in comparison to the similarly treated 36 hour sample, Tukey’s HSD
test show significant increases for the LAM1-116 mAb treated splenic sample,
with a P=0.02 (n=7) compared to SLC treatment alone, and a P=0.04 (n=7)
compared to LAM1-101 mAb treatment.
iii. Transmigrating cell subsets show homogeneity regardless of treatment
The significant levels of proliferation in bulk populations at the 36 and 72
hour mark gave us an impetus to determine if these enhanced proliferation levels
were present in both the CD4+ and CD8+ T cell subsets. We initially chose to
focus on T cells due to the higher density of L-selectin and CCR7 expression in
these cells in comparison to B cells. Furthermore, activation in B cells seems to
result in CCR7 up-regulation which is in opposition to the T cell-specific effect
(94).
The transmigration step before the proliferation assay was a potential
pitfall because it was possible that there would be a transmigration bias towards
a particular subset and thus affect subset proliferation results. Fortunately, there
were no statistical variances between treatment groups as to the proportion of
transmigrated CD4+ and CD8+ T cell subsets as shown in representative dot
plots (Figure10, upper left and lower right quadrant numbers) or as shown in
summary data (Figure 11). Specifically, the frequency of transmigrated splenic
CD4+ T cells regardless of treatment was not varied (n=7, P=0.91) at a range of
21±1.2%. The results were similar for splenic CD8+ T cells at a range of 17±2%
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with a variance of P=0.98 (n=7). PLN CD4+ T cells also showed no variance
between treatments at P=0.99 (n=7). CD8+ T cells from the PLN also were not
statistically varied at a P=0.97 (n=7).
The homogenous proportions of both T cell subsets in all treatments
allowed us to undertake the subsequent experiments with ease and without bias
iv. Spleen and PLN CD4+ T cells treated with SLC and LAM1-116 mAb have
increased proliferation at 36 and 72 hours post-TCR stimulation
To determine the effects of L-selectin activation among the CD4+ T cell
subset, we labeled samples for CD4 and determined the frequency of
proliferating cells in the treatment groups as discussed in the previous
experiments. After gating for cells that exhibited the side and forward light scatter
properties of mononuclear cells, CD4+ T cells as distinguished by PE-conjugated
antibody staining, were analyzed for CFSE intensity, to examine proliferation
using the same strategy as outlined in the previous experiments. A
representative experiment illustrating an increase in CD4+ T cell proliferation as
compared to the negative control is shown in Figure 12. Comparing the SLCtreated sample to the negative control, an increase from 61% to 66% was found
in the spleen sample (Figures 12 A and B), and an increase from 44% to 48%
was found in PLN samples (Figures 12 E and F). The SLC+LAM1-101 mAbtreated samples showed similar increases in comparison to the negative control
for both splenic and PLN samples but show an equal increase in proliferation
when compared to the SLC-treated sample alone (Figures 12 A and D, and
Figures 12 E and H, respectively). Interestingly, the SLC+LAM1-116 mAb-treated
samples showed the highest increases in proliferation (12 C and G).
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The increases outlined above were statistically significant, as shown in the
summary data (Figure 13), with variance in the spleen sample, after data
transformation, at P=0.01 (n=7) and for the PLN sample with P=9x10-4 (n=7). In
the spleen, the increase in the SLC+LAM1-116 mAb-treated sample compared to
the SLC-treated cells was significant at P=0.01 (n=7), or with the SLC+LAM1-101
mAb-treated sample P=0.03 (n=7). In the PLN, the same levels of significance
were noted with P=0.01 (n=7) between LAM1-116 mAb treated SLC
transmigrated cells versus SLC-treated alone transmigrated cells. The increase
in proliferation for the LAM1-116 mAb treatment as compared to the LAM1-101
mAb treatment was also statistically significant with a P=0.02 (n=7).
In the samples analyzed 72 hours post stimulation, all samples showed
increased proliferation over the 36 hour sample. In the representative histograms
shown in Figure 14, all SLC-treated samples showed appreciable increases in
proliferation when compared with the untreated negative control. As expected,
the LAM1-116 mAb-treated samples showed the highest increase in proliferation.
The

summary

data

(Figure

15)

reflects

the

above

described

enhancements with the splenic and PLN samples showing significant variance at
P=0.01 (n=5) and P=0.03 (n=5), respectively. In the spleen, the Tukey’s HSD test
showed statistical difference between the SLC- vs. SLC+LAM1-116 mAb-treated
samples with a P= 0.01 (n=5). A similar difference in the same tissue was found
between the SLC+LAM1-101 mAb- vs. SLC+LAM1-116 mAb-treated samples
with a P=0.03 (n=5). In the PLN, the Tukey’s HSD test showed significant
differences between the LAM1-116 mAb-treated sample vs. SLC alone with a

38
P=0.05 (n=5), and with the LAM1-101 mAb-treated sample with a P=0.04 (n=5).
Taken together, these results strongly support the idea that L-selectin activation
prior to SLC-induced chemotaxis significantly enhances CD4+ T cell proliferation
through the TCR, regardless of tissue origin.
iv. Spleen and PLN CD8+ T cells treated with SLC and LAM1-116 mAb have
increased proliferation at 36 and 72 hour post-TCR stimulation
Analysis of CD8+ T cells showed enhancements that mirrored the effects
seen in CD4+ T cells. Representative data (Figure 16) showed increased
proliferation for all SLC-treated samples compared to the negative control. As
expected, the SLC+LAM1-116 mAb-treated sample showed the highest
enhancement in proliferation. The summary data (Figure 17) demonstrates
statistical significance in the 36 hour samples with the spleen and PLN showing
significant variances of P=0.003 (n=8) and P=4.9x10-5 (n=9), respectively. In the
splenic sample, Tukey’s HSD test for the SLC+LAM1-116 mAb treated sample
vs. the SLC alone treatment or SLC+LAM1-101 mAb treated was significant with
P=0.007 (n=8) and P=0.009 (n=8), respectively. The same trend was seen in the
PLN with comparison between the SLC and SLC+LAM1-116 mAb groups
showing a P=6.2 x10-5 (n=9), and the SLC+LAM1-116 to SLC+LAM1-101 mAb
treated groups showing a P=9.2x10-4 (n=9).
For the CD8+ T cell analysis for 72 hour proliferation, all proliferation levels
increased, similar to the 72 hour CD4+ proliferation. Representative data shown
in Figure 18 demonstrates similar increases for all SLC-treated samples, with the
LAM1-116

mAb-treated

sample

showing

the

highest

enhancement

in

proliferation. Variance between treatments after data transformation was
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significant for both the spleen and PLN, with P=0.0004 (n=5) and P=0.002 (n=5),
respectively (Figure 19). In the PLN, post hoc tests showed HSD values to be
significant between the SLC+LAM1-116 mAb-treated sample vs. SLC alone or
SLC+LAM1-101 mAb treatment (n= 5, P=0.002; n=5, P=0.02, respectively). In
the spleen, Tukey’s HSD test also showed significant differences between the
SLC+LAM1-116 mAb treated samples vs. the SLC-treated alone sample (n=5,
P=0.0005) or the SLC+LAM1-101 mAb-treated sample (n=5, P=0.002). Thus,
these findings of L-selectin-mediated increases in CD8+ T cell proliferation are in
good agreement to the results seen in CD4+ T cells.
v. Samples treated with SLC and LAM1-116 mAb showed higher frequencies of
CD4+ and CD8+ T cells at the terminal divisions for samples reaching asymptotic
growth.
To address the limitations of samples reaching asymptotic growth at the
72 hour time point, and thereby providing no distinguishable differences between
samples, we decided to analyze dividing subpopulations (Figure 20). To this end,
we isolated 3 samples from both the spleen and PLN that showed at least 3
discernible division peaks. These peaks had to show a MFI of at least half of the
preceding peak to be considered for analysis. Without exception, SLC+LAM1116 mAb-treated samples showed a higher frequency of both CD4+ and CD8+ T
cells in the terminal division (P5, Table 1). In splenic CD4+ T cells, the LAM1-116
mAb-treated sample showed a doubling of cells in the G5 subpopulation vs. all
other treatments. A similar result was also observed for the splenic CD8+ T cells.
In the PLN, CD4+ T cells treated with LAM1-116 mAb showed the highest
means compared to all other treatments. CD8+ T cells in the same tissue also
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showed similar increases in cell frequency at the terminal division, when
compared to SLC treatment alone or the SLC+LAM1-101 mAb treatment group.
Unfortunately, the variability between experiments along with the small n, did not
allow us to find any significant differences. Transforming the data set similar to
the steps outlined in the previous experiments provided no relief from the large
variances or did not eliminate normality outliers. Using power analysis
(power=0.80) an n=44.5 would be required to overcome this statistical quandary.
vi. Frequency of L-selectin+ cells and enhanced proliferation do not show a
correlation.
While virtually all naïve T cells express high levels of L-selectin, subsets of
effector and memory T cells express low to negative levels (95). Using Pearson’s
correlation, we then embarked on determining whether the frequency of Lselectin positive cells effected proliferation. All transformed proliferation numbers
were compared to the frequency of L-selectin positive cells in each sample,
corresponding to all cell populations regardless of tissue origin and subset.
Pearson’s r for L-selectin frequency vs. 36 hour proliferation showed an r=0.01,
indicating no relationship between the two variables whatsoever. The same was
detected in the 72 hour time point with r=0.00. However, visualizing the data set
(Figure 21), one can see a minor positive r value for L-selectin frequency vs. the
72 hour proliferation levels. The presence of outliers may have negated this
effect, with a steep decline of correlation at the highest levels of proliferation.
Interestingly, there is significant positive correlation between the 36 and 72 hour
proliferation time points with an r=0.37, P=0.0085. An alternative approach to
discern whether the frequency of L-selectin+ cells affect proliferation would be to
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subject the samples to multi-variate analysis, perhaps by using MANOVA or
using a general linear model (GLM). However, because the frequency L-selectin+
cells between tissues and subsets do not have an appreciable difference,
analysis of L-selectin+ cell effects may prove unattainable.
4. Discussion
The bulk of the results from the current studies point to a general
contribution of L-selectin activation to T cell proliferation. This effect is most likely
directly related to L-selectin activation since the antibody used was a monoclonal
antibody that has previously been shown to bind to the activation (i. e., lectin)
domain of L-selectin (10). This is in comparison to the lack of response of cells
treated with the control antibody that also binds L-selectin but at a region
distinctly distant from the activating site. The current results also show that
activation through CCR7 via SLC contributes to increases in TCR-mediated
proliferation. However, while SLC activation alone did induce a modest increase
in T cell proliferation, the highest level of proliferation was exclusively found in
the L-selectin-activated samples. In regards to subset analysis, because of the
transmigration step prior to TCR-induced proliferation, it was possible that
subsets could show a distinct preference for chemotaxis based on mAb
treatment or chemokine used. This would have a dire consequence on subset
bias. If the SLC+LAM1-116 mAb treatment induced higher levels of CD4+ or
CD8+ T cell migration in comparison to the SLC- or SLC+LAM1-101 mAb-treated
samples, the sheer difference in cell proportion between treatments could be the
simple explanation for any observed proliferative effects. However, subset
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analysis of treatment populations indicated homogenous populations negating
any population effects that may have rendered our analysis invalid (Figure 11).
In the 36 hour post-TCR stimulation analysis, proliferation levels were
significantly higher in the LAM1-116 mAb-treated, SLC transmigrated samples.
The PLN bulk sample showed a distinct higher increase in proliferation compared
to the spleen bulk sample (Figure 7). This is reasonable because of the higher
proportion of T cells in this tissue, which in turn have higher expression levels of
L-selectin (4). Similarly, CD4+ T cells from the PLN also showed a better
response to LAM1-116 mAb treatment compared to the corresponding splenic
sample. This most likely reflects the finding that 88±3% of PLN CD4+ cells
expressed high levels of L-selectin in comparison to 80±2% for splenic CD4+ T
cells (data not shown). In regards to CD8+ T cells, the increase in proliferation
was opposite of that observed for CD4+ T cells. Specifically proliferation of
splenic CD8+ T cells treated with LAM1-116 mAb surpassed that similarly treated
PLN CD8+ T cells by at least 10% (131±6% vs 120±2%, respectively). This was
unexpected due to higher levels of L-selectin+ CD8+ T cells in the PLN. However,
the nature of the CD8+ T cells in each tissue also has to be taken into account.
CD8+ T cells of the central memory phenotype may be present in higher numbers
in the spleen and therefore may exhibit a more responsive proliferative effect
compared to naïve cells that have just recently transmigrated to the PLN. Central
memory cells are products of clonal expansion during antigenic encounter which
possess the ability to migrate between the blood and parenchyma. This
population has been known to be more reactive and more efficient in clearing
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antigenic challenges (96). Furthermore, the difference in L-selectin+ CD8+ T cells
that are between compartments were negligible at less than 2%, with the PLN
residents at the high end (data not shown). Another possible explanation for this
difference is the nature of the microenvironment from where the cells originated.
T lymphocytes and therefore CD8+ T cells are not the dominant cell type in the
spleen. In the transmigrated population analyzed via flow cytometry, less than
50% of splenic cells were T cells as compared to almost 80% of PLN cells
(Figure 11). A possible population that may create an environment in which CD8+
T cells from the spleen proliferate better may be the CD56dim natural killer cells.
This NK subset is more abundant in the spleen and has been shown to be more
prolific in responding to antigen and produces high levels of pro-inflammatory
cytokines at early stages of antigenic encounter (97-98). Another interesting
finding came from comparing CD4+ versus CD8+ T cells in the same tissue.
Although, the CD8+ T cells in the spleen showed a better response to L-selectinmediated signaling compared to splenic CD4+ T cells, this was not the case in
the PLN. In the PLN, CD4+ T cells proliferated better than CD8+ T cells following
L-selectin engagement (Figure 13 and 14). We expected CD8+ T cells to have a
more robust response to LAM1-116 mAb treatment because of the frequency of
L-selectin positive cells for this subset (93.5±0.5%) in comparison to the CD4+ T
cells (87±1%) (data not shown). Additionally, experiments using bulk populations
also showed a better predisposition of PLN lymphocytes to proliferate compared
to the spleen (Figure 7). A possible explanation for this difference is the larger
proportion of CD4+ T cells in the PLN transmigrating population (Figure 11). This
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PLN CD4+ T cell population is distinct from that of the spleen due to the higher
frequency of L-selectin positive cells. Another contributing factor to the
enhancement in CD4+ T cell proliferation in this tissue may be the higher density
of dendritic cells (99). Dendritic cells are extremely efficient at presenting antigen
and activating CD4+ T cells and thus their increased presence in the PLN
samples may contribute to the observed enhanced proliferation.
In the 72 hour samples, the results were much clearer. As expected, all
LAM1-116 mAb-treated samples produced the greatest proliferative responses
(Figures 9, 15 and 19). In the bulk populations, both tissue samples were almost
identical in proliferation enhancement. As discussed before, we expected a more
robust response in the PLN proportional to the increased frequency of L-selectin+
cells. It must be noted that at the 72 hour time point, most of the samples
regardless of treatment had reached 90% or higher levels of proliferation
(Figures 8, 14 and 18). Therefore, the differences between tissues were less
distinct. Regardless of this convergence on asymptotic growth for the bulk
populations, our expectations were supported for cell subsets in all tissues. In the
spleen and PLN, the CD8+ T cell subset exhibited a higher degree of proliferation
enhancement over the CD4+ T cell subset, consistent with the frequency of Lselectin+ cells (Figures 15 and 19). PLN residents also showed a higher level of
proliferation enhancement over their splenic counterparts, again consistent with
L-selectin+ cell frequency (Figures 15 and 19).
To determine the preference of subsets reaching a terminal division, we
utilized samples reaching asymptotic growth and compared the frequency of
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each T cell subset per terminal division (Figure 21, Table 1). This particular
experiment was only performed with samples reaching asymptotic growth
because samples reaching submaximal growth do not exhibit the same number
of cell divisions and thus a true comparison between samples cannot be made.
In all tissue subsets, L-selectin activation resulted in more cells reaching terminal
division (Table 1). Furthermore, CD4+ spleen T cells, which contained the lowest
frequency of L-selectin+ cells, also displayed the lowest rates of terminal division.
As expected, CD8+ T cells and PLN residents displayed the highest rates of
terminal division with the PLN CD8+ T cells exhibiting the highest rate. However,
the variance between samples made the data set inconclusive but with trends
following our predictions. The variance problem can be easily solved by
increasing the sample size. However, at the 72 hour time point post-stimulation,
finding treatments that have reached asymptotic growth is not definite. This
problem could be easily solved by moving time points farther forward, possibly to
4 or 5 days post stimulation. Another problem that arose from this study was the
non-linear relationship between the frequency of L-selectin+ cells and
proliferation as outlined in Figure 21. Just by visual inspection, no correlation
between L-selectin frequency and the two time points could be detected. In the
36 hour proliferation time point, no correlation could be ascertained statistically or
visually (Figure 21A and 21C). In the 72 hour data set, a positive correlation
between L-selectin frequency and proliferation was apparent at the lower levels
that increased proportionally as L-selectin frequency increased (Figure 21E).
However, there was a decline in the relationship in the latter parts of the figure,
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thus, negating the initial positive correlation. Interestingly, there was a clear
positive correlation between the 36 hour and 72 hour time points of proliferation,
indicating that cells that have proliferated better at 36 hours also proliferated
better at the 72 hour time point.
Aside from the minor issues outlined previously, our data shows that Lselectin activation contributes to the ability of T cells to proliferate in response to
signaling. Because this study is singularly based on phenotypic analysis in vitro,
we are hampered by our inability to pinpoint a mechanism for such proliferative
effects. To this end, we propose the following mechanistic model.
It has been shown that the cytoplasmic tail of L-selectin associates with
CaM (100-102). The cytoplasmic tail is also known to associate with ezrin radixin
moesin (ERM) proteins (101, 39). Based on these observations, a model of Lselectin multimerization involving CaM and ERM binding adjacent L-selectin
molecules was proposed (101). It is known that L-selectin activation oftentimes
involves ectodomain shedding (103-104), which in turn disrupts cytoplasmic tail
associations. Subsequently, CaM and ERM proteins are released exposing the
two serine residues in the cytoplasmic tail that in turn has been shown to be
phosphorylated (84). What happens after? This phosphorylation step most likely
mediates a response because it is difficult to understand why a molecule would
be phosphorylated and not used.
It has previously been shown that L-selectin can bind growth factor
receptor-bound protein 2/son of sevenless (Grb2/SOS), and activate the Ras
pathway (105). However, Grb2/SOS binding requires a Src homology 2 (SH2)

47
binding domain which is not present in the L-selectin cytoplasmic tail. It should be
noted that SH2 domains bind to phosphorylated tyrosine residues and L-selectin
does possess a terminal tyrosine residue in the cytoplasmic domain that can
potentially be phosphorylated. However, this is unlikely because of its terminal
position and the absence of an SH2 domain. A likely candidate that could bridge
L-selectin and Grb2/SOS binding is the 14-3-3 protein. The cytoplasmic terminal
amino acid sequence of mouse L-selectin (RRLKKGKKSQERMDDPY), and
human

L-selectin

(RRLKKGKKSKRSMNDPY),

both

show

a

potential

homologous sequence to the putative 14-3-3 binding mode 1 sequence of
RSXpSXP (106, the bold serine residue indicates required phosphorylation).
Although the sequence of the L-selectin tail is not 100% complementary to the
putative binding domain, it must be noted that 14-3-3 can bind to some proteins
displaying a dissimilar sequence as in the case of insulin-like growth factor-1
(107), or insulin receptor substrate-1 (108). The ability of 14-3-3 to bind to
regions without complete complementarity seems to rest on its ability to utilize a
14-3-3 dimer as well as dual phosphoserine residues for partner binding (109). It
is then possible that 14-3-3 binding to the L-selectin tail can recruit Grb2/SOS. It
must be noted that Grb2 and 14-3-3 possess SH2 and Src homology 3 (SH3)
domains, respectively. It has been shown that SH2 and SH3 domains can
interact with each other (110-112).
In light of the possibility of L-selectin+14-3-3 binding and the eventual
recruitment of the Grb2/SOS dimer, one can now see that the potential of Ras
sarcoma protein (Ras) involvement is quite likely. The Grb2/SOS and Ras
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relationship has been firmly established. SOS serves as a guanine exchange
factor (GEF), and its primary role is in the transition for Ras to exchange its
bound GDP to GTP (113-115). The GDP to GTP transition activates Ras (116).
Importantly, it must be noted that the same paper by Brenner in 1996, also
showed Ras involvement. The involvement of Ras is expected with the diversity
of signaling molecules that are activated during L-selectin activation. Specifically,
reports have shown that L-selectin activation involves Rac protein (117), p38
mitogen activated protein kinase (MAPK) (118), urokinase receptors (119), light
chain kinase (Lck) (120), in addition to others. The Ras pathway is logical
because most of the signaling molecules outlined above are downstream events
of Ras activation. Furthermore, Ras is an oncogenic protein responsible for
proliferation signals in tumorigenic cells, in parallel to our proliferation assays.
The

proposed

mechanism

of

phosphorylated

L-selectin+14-3-

3+Grb/SOS+Ras is a very plausible one in relation to enhancement that has
been reported in other cell mechanisms. In the Subramanian paper (6), an Lselectin signaling contribution to CCR7-mediated chemotaxis was described.
SOS is a guanine exchange factor, responsible for the GDP-GTP transition, in its
function, as well as the function of other molecules. The G subunit of G-protein
coupled receptors (GPCR) requires a transition from GDP to GTP, which is
normally catalyzed by a GPCR ligand docking to the receptor. It is foreseeable
that SOS can also induce this GDP-GTP exchange in GPCR’s, activating them in
the absence of ligand, and in our case enhancing the activity of CCR7 in the
presence of its ligand, SLC. This indirect relationship between L-selectin and
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proliferation by way of Ras also explains the absence of significant correlation in
our study (Figure 21). The TCR-induced proliferation may have masked any
contributions to proliferation by L-selectin, with TCR-induced proliferation being
much stronger than L-selectin-induced proliferation. This could also explain the
small amounts of LAM-116 mAb-induced proliferation observed relative to the
control.
The proposed mechanism outlined above directly supports the L-selectininduced enhancement in TCR-mediated proliferation outlined in this thesis as
well as the chemotactic enhancement reported previously (6). Further work to
clarify the molecular mechanisms must be undertaken to provide a better
understanding of the underlying mechanism and lend additional support for our
proposed model.

Figure 6. Representative proliferation histograms of spleen and PLN lymphocytes at 36 hours post-TCR stimulation. Cells were isolated from
Spleen (A-D) and PLN (E-H), and stained with 0.25 M of CFSE (intensity shown on the X axis). Some samples were treated with 10 g/mL of the
L-selectin activating mAb, LAM1-116, before transmigration in the presence of 500 ng/mL of SLC (SLC+LAM1-116, C and G). Other samples were
transmigrated to the same concentration of SLC with no mAb treatment (SLC, B and F) or treated with 10 g/mL of a control mAb, LAM1-101
(SLC+LAM1-101, Figures D and H). Cells that transmigrated to media alone without mAb treatment are considered negative (Figures A and E). All
4 treatment subsets were subsequently induced to proliferate in the presence of anti-CD3 and anti-CD28 mAbs in a 96 well plate. Numbers in red
indicate the frequency of actively proliferating cells. Proliferating cells were identified as the population flanked by a non-CFSE stained sample
(dashed line) and a non-proliferated CFSE stained sample (dotted line). Both controls were from the same population as the treated samples and
were analyzed at the same time point. Results are representative of 10 and 9 experiments for spleen and PLN, respectively.
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Figure 7. Summary data of spleen and PLN lymphocyte proliferation at 36 hours post-TCR stimulation. Results are from experiments shown in
Figure 6. All numbers (mean±SEM) are in comparison to a proliferated and CFSE-stained control sample exposed to media alone
(Treatment/Control*100). In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=10, P=0.04; n=9,
P=0.01; respectively. In the spleen, post hoc Tukey HSD tests showed no significant difference between the LAM1-116 treated sample compared
to the sample treated with SLC alone, n=10, P=0.06, or the sample treated with SLC along with the control mAb, LAM1-101, n=10, P=0.09. In the
PLN, the differences between groups were significant in both cases: n=9, P=0.01; n=9, P=0.04; respectively. Statistical analysis was performed
using R version 2.15.2. * indicates PAnova<0.05. ** indicates PTukey HSD<0.05. ns indicates not significant.
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Figure 8. Representative proliferation histograms of spleen and PLN lymphocytes at 72 hours post-TCR stimulation. Cells were isolated from
Spleen (A-D) and PLN (E-H), and stained with 0.25 M of CFSE (intensity shown in the X axis). Samples were treated as described in Figure 6
and analyzed 72 hours following TCR stimulation. Numbers in red indicate the frequency of actively proliferating cells. Proliferating cells were
identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-proliferated CFSE stained sample (dotted line). Both
controls were from the same population as the treated samples and were analyzed at the same time point. Results are representative of 6 and 7
experiments for spleen and PLN, respectively.

52

Spleen

PLN

Figure 9. Summary data of spleen and PLN lymphocyte proliferation at 72 hours post-TCR stimulation. Results are from experiments shown in
Figure 8. All numbers (with SEM bars) are in comparison to a proliferated and CFSE-stained control sample exposed to media alone
(Treatment/Control*100). In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=7, P=0.015; n=6,
P=0.016; respectively. In the spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to
the sample treated with SLC alone, n=7, P=0.02, or the sample treated with SLC along with the control mAb, LAM1-101, n=7, P=0.04. In the PLN,
the differences between groups were significant in both cases: n=6, P=0.05; n=6, P=0.02; respectively. Statistical analysis was performed using R
version 2.15.2. * indicates PAnova<0.05. ** indicates PTukey HSD<0.05.
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Figure 10. Representative subset dot plots of transmigrated cells. Cells were isolated from spleen (A-D) and PLN (E-H), and treated as described
+
+
in Figure 6. After chemotaxis, wells for the same treatment were pooled and subset frequencies for CD4 T cells (x axis) and CD8 T cells (y axis)
in the transmigrated population were determined using flow cytometry. Numbers in red indicate the frequency of cells in each quadrant. No
significant variations between treatment groups were detected. Results are representative of 7 experiments.
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Figure 11. Summary data of transmigrated cell subset analysis. Data was obtained from the experiments shown in Figure 10 (n=7 independent
experiments). ns indicates not significant.
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Figure 12. Representative histograms of proliferating CD4 T cells at 36 hours post-TCR stimulation. Cells were isolated from spleen (A-D) and
PLN (E-H), and treated as described in Figure 6 except that the samples were labeled for CD4 expression. Numbers in red indicate the frequency
+
of actively proliferating CD4 T cells. Proliferating cells were identified as the population flanked by a non-CFSE stained sample (dashed line) and
a non-proliferated CFSE stained sample (dotted line). Both controls were from the same population as the treated samples and were analyzed at
the same time point. Results are representative of 7 independent experiments per tissue.
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Figure 13. Summary data of CD4 T cell proliferation at 36 hours post-TCR stimulation. Results are from experiments shown in Figure 12. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
In both the spleen and PLN, variances (one-way ANOVA) between treatments was significant, n=7, P=0.01; n=7, P=0.0009; respectively. In the
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 mAb treated sample compared to the sample treated with
SLC alone, n=7, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=7, P=0.03. In the PLN, the differences between
groups were significant in both cases: n=7, P=0.01; n=7, P=0.02; respectively. Statistical analysis was performed using R version 2.15.2. *
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.
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Figure 14. Representative histograms of proliferating CD4 T cells at 72 hours post-TCR stimulation. Cells were isolated from Spleen (A-D) and
PLN (E-H), and treated as described in Figure 12. Numbers in red indicate the frequency of actively proliferating cells. Proliferating cells were
identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-proliferated CFSE stained sample (dotted line). Both
controls were from the same population as the treated samples and were analyzed at the same time point. Results are representative of 5
independent experiments.
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Figure 15. Summary data of proliferating CD4 T cells at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 14. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=5, P=0.01; n=5, P=0.03; respectively. In the
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC
alone, n=5, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=5, P=0.03. In the PLN, the differences between
groups were significant in both cases: n=5, P=0.05; n=5, P=0.04; respectively. Statistical analysis was performed using R version 2.15.2. *
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.
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Figure 16. Representative histograms of proliferating CD8 T cells at 36 hours post-TCR stimulation. Cells were isolated from spleen (A-D) and
PLN (E-H), and treated as described in Figure 6 except that the samples were labeled for CD8 expression. Numbers in red indicate the frequency
of actively proliferating cells. Numbers show increased proliferation in all SLC treated cells, with the LAM1-116 mAb treated sample displaying the
highest proliferation. Proliferating cells were identified as the population flanked by a non-CFSE stained sample (dashed line) and a nonproliferated CFSE stained sample (dotted line). Both controls were from the same population as the treated samples and were analyzed at the
same time point. Results are representative of 8 and 9 independent experiments for the spleen and PLN, respectively.
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Figure 17. Summary data of CD8 T cell proliferation at 36 hours post-TCR stimulation. Results are from experiments shown in Figure 16. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
-5
In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=8, P=0.003; n=9, P=4.9x10 ; respectively. In the
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC
alone, n=8, P=0.007, or the sample treated with SLC along with the control mAb, LAM1-101, n=8, P=0.009. In the PLN, the differences between
-5
-4
groups were significant in both cases: n=9, P=6.2x10 ; n=9, P=9.2x10 ; respectively. Statistical analysis was performed using R version 2.15.2. *
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.

61

+

Figure 18. Representative histograms of proliferating CD8 T cells at 72 hours post-TCR stimulation. Cells were isolated from spleen (A-D) and
PLN (E-H), and treated as described in Figure 16. Numbers in red indicate the frequency of actively proliferating cells. Proliferating cells were
identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-proliferated CFSE stained sample (dotted line). Both
controls were from the same population as the treated samples and were analyzed at the same time point. Results are representative of 5
independent experiments per tissue.
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Figure 19. Summary data of proliferating CD8 T cells at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 18. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=5, P=0.0004; n=5, P=0.002; respectively. In the
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC
alone, n=5, P=0.0005, or the sample treated with SLC along with the control mAb, LAM1-101, n=5, P=0.002. In the PLN, the differences between
groups were significant in both cases: n=5, P=0.002; n=5, P=0.02; respectively. Statistical analysis was performed using R version 2.15.2. *
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.
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Figure 20. Representative histogram of a 72 hour sample post-TCR stimulation that had reached asymptotic growth. Samples were treated as
described in Figure 6. The area bound by the negative control (dotted and dashed line) and positive control (dashed line) was analyzed for
divisions (Progeny:P0-P5).Divisions must exhibit mean fluorescence intensity of approximately half of the preceding peak to be considered for
+
+
analysis. The frequency of CD4 and CD8 T cells in each division were then analyzed. Result is representative of 3 independent experiments per
tissue.
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Figure 21. Correlogram of L-selectin positive cell frequency versus 36 and 72 hour proliferation. Data is from experiments shown in Figures 6-19.
+
+
L-selectin (LAMFrequency) from both CD4 and CD8 T cells were then compared to proliferation levels using Pearson’s correlation. Dot plots
+
illustrates proliferation levels (x axis) versus L-selectin cells (y axis) at both 36 (A) and 72 (B) hours. Results were statistically not significant with r
values of 0.00 and 0.01 (n=50), respectively. Interestingly high proliferation levels at the 36 hour time point positively correlates with proliferation
levels at 72 hours (n=50, r=0.37, P=0.0087), shown in figures D and F. Figures C and E are best fit lines for the dot plots for the 36 and 72 hour
time points respectively. Statistical analysis was performed using R version 2.15.
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Table 1. Population analysis of cell division population at 72 hour post-TCR stimulation. Results are from experiments shown in Figure 20 (n=3).
+
+
Results between treatments in the G4 and G5 populations, although showing greater frequencies of CD4 and CD8 T cell subsets in the
SLC+LAM1-116 treated samples, were not significant.
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Chapter 3: Characterization of T cell apoptosis during simultaneous
activation of L-selectin and CCR7
1. Research design
The effects outlined in Chapter 2 of L-selectin-mediated enhanced TCRinduced proliferation could be a product of two effects separately or in synchrony.
Specifically, these effects could be a result of: 1) populations that truly respond
by increasing cell proliferation, 2) cell samples showing a decrease in the rate of
cell death (apoptosis) and finally, 3) a contribution by both phenomena. In
relation to the effects listed above, signaling through several adhesion molecules
has been implicated in lowering rates of apoptosis (121-122). Interestingly, in
some reports, apoptosis and proliferation were inversely related following
activation of adhesion molecules (123-124). Transmigration as a cellular process
has also been shown to inhibit apoptosis. This is true for neutrophils exposed to
stimulation by bacterial lipopolysaccharide (125). However, in the previously
mentioned paper, L-selectin engagement was positively associated with
apoptosis. By contrast, others studies have shown that the apoptotic rate of
peripheral mononuclear cells was inversely related to L-selectin expression
levels (126). To ascertain whether our observed increased proliferative effect of
L-selectin engagement was from either a combination of enhanced proliferation
and lower apoptosis or a stand-alone effect; a corresponding assay for apoptosis
was utilized using propidium iodide (PI). PI staining can be used as a
fluorescence method for determining cell viability. PI can intercalate double
stranded nucleic acids if the cell membrane is permeable. Thus, cells that are
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apoptotic and have compromised cellular membranes allow PI to diffuse in,
resulting in a nuclear fluorescence that can be detected.

2. Materials and Methods
i. Cell Isolation and Sample Treatment
Please refer to chapter two for protocols for cell isolation and experimental
conditions.

ii. Apoptosis Assay
In some experiments, cells from the same time points were analyzed for
apoptosis with PI (Molecular Probes, Carlsbad, CA) staining. Cells prepared as
described in the previous experiments and exposed to the same conditions were
analyzed. Cell subset antibody staining was performed as previously described,
along with addition of 5 g/mL of PI. In this case, antibody and PI staining
incubations were performed in the dark at room temperature for 30 minutes. This
assay was performed at the 36 and 72 hour time points, post-TCR stimulation, in
parallel to the proliferation assays described in chapter 2. To detect cells
undergoing stages of apoptosis, only cells that were in the live resting
lymphocyte and actively dividing lymphoblast gate were considered. Thus, cells
in the lymphocyte/lymphoblast gate which were also PI positive were considered
to be apoptotic cells. The frequency of apoptotic cells of the sample treated with
media alone was compared to the other treatment samples. A ratio of less than
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100% indicated a decrease in apoptosis whereas numbers higher than 100%
indicated an increase in apoptosis.
iii. Data Analysis
After analyzing the raw data for homogeneity of variance with the Bartlett
test and normality with a Q-Q line plot, deviations were detected that proved the
raw data unusable. To correct for these departures from normality and variance
all data were normalized as follow:
%Apoptotic Improvement = (frequency of apoptotic cells in the treated
sample/frequency of apoptotic cells in the untreated sample)* 100
Transformed data were subjected to normality and variance tests, through
Q-Q line plot and Bartlett tests, respectively. No significant departures were
noted or the residuals of the outliers did not impact the outcome of the factors.
Data were then analyzed with one-way ANOVA. If data sets showed significant
variance (p < 0.05), further analysis between groups was performed using the
Tukey Honestly Significant Difference (HSD) test. A P value of less than 0.05
was considered significant. Pearson correlation was also performed between
apoptosis versus frequency of L-selectin positive cells. All data analysis was
performed using R 2.15.2 (R Foundation for Statistical Computing, Vienna,
Austria).
3. Results
i. CD4+ T cell apoptosis at 36 hours post-TCR stimulation.
To ascertain if anti-apoptotic activity can also contribute to the increase in
TCR-induced proliferation described in Chapter 2, subset apoptotic effects were
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analyzed. In the CD4+ T cell subset at 36 hours, no detectable differences
between samples were detected regardless of tissue origin. In the spleen, CD4 +
T cells that were also PI positive (apoptotic cells, upper right hand quadrants,
Figures 22 A-D), show results that are relatively similar to each other with 6.16%
(negative), 6.59% (SLC), 6.2% (SLC+LAM1-116) and 6.8% (SLC+LAM1-101).
This was also the case with CD4+ T cells from the PLN with apoptotic cell
frequencies of 4.83% (negative), 5.25% (SLC), 5.28% (SLC+LAM1-116) and
5.73% (SLC+LAM1-101) (Figures 22 E-H). Transforming the data relative to
control, similar to the approach taken for proliferation in chapter 2 also showed
the same result. In this regard, % Apoptotic Improvement<100%, indicates a
lower rate of apoptosis relative to control. No variances were found between
treatment groups in the spleen (n=4, P=0.511) or PLN (n=4, P=0.275).
Interestingly, looking at the summary data (Figure 23), a trend of increased
apoptosis for all treatment groups, with the LAM1-116 mAb-treated sample
displaying the highest level, was observed.
ii. CD4+ T cell apoptosis at 72 hours post-TCR stimulation
The data from the apoptotic analysis of CD4 + T cells at 72 hours poststimulation showed a distinct departure from the 36 hour time point. Looking at a
representative spleen dot plot, one can see the LAM1-116 mAb-treated sample
displaying the lowest frequency of CD4+ apoptotic cells at 6.5% (Figure 24). This
is in comparison to the control- (9.75%), SLC- (9.73%) and SLC+LAM1-101 mAb
(9.21%) -treated cells (Figures 24, A-B and D). This was similar to the results
from PLN CD4+ T cell

samples at the same time point, which displayed an
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apoptotic frequency of 15.99% for the SLC+LAM1-116 mAb treatment compared
to 20.97% (negative), 17.2% (SLC) and 18.81% (SLC+LAM1-101) (Figures 24 EH). The transformed summary data are shown in Figure 25. The LAM1-116 mAbtreated CD4+ splenic sample showed a mean % apoptotic improvement±SEM of
73.44±7.30, compared to 87.89±4.56 (SLC) and 84.62±4.40 (SLC+LAM1-101)
(Figure 25). The variance between groups was significant at P=0.007 (n=4), with
post hoc Tukey HSD tests showing significant difference between the LAM1-116
mAb- and SLC-treated samples (n=4, P=0.01) or the SLC+LAM1-101 mAbtreated sample (n=4, P=0.02). In the PLN, the values were similarly decreased in
the LAM1-116 mAb-treated sample (77.10±5.31) compared to the SLC-treated
sample (89.11±5.02) and the SLC+LAM1-101 mAb treated sample (88.01±3.68).
The variance between groups was similarly significant at P=0.01 (n=4) and the
Tukey HSD tests between the LAM1-116 mAb-treated sample compared to the
SLC treatment (n=4, P=0.01) and SLC+LAM1-101 mAb treatment (n=4, P=0.02)
both showed significance (Figure 25). These data indicate that activation through
L-selectin exerts an anti-apoptotic effect in CD4+ T cells that is discernible at 72
hours post-TCR stimulation.

iii. CD8+ T cell apoptosis at 36 hours post-TCR stimulation
Similar to the results for CD4+ T cells, CD8+ T cell apoptosis was
unaffected by L-selectin activation at the 36 hour post-TCR stimulation time
point. The representative dot plot for this experiment shows splenic CD8+ T cell
apoptotic frequencies with minor variations at 8.95% (negative), 9.43% (SLC),
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8.9% (SLC+LAM1-116) and 9.92% (SLC+LAM1-101) (Figure 26 A-D). The mean
% Apoptotic Improvement±SEM (n=5) for this experiment confirms this lack of
effect with SLC=112±2.77%, SLC+LAM1-116=134±9.35% and SLC+LAM1101=116±4.13% (Figure 27). The variance for the spleen and PLN were P=0.276
and P=0.24, respectively (n=5 for both tissue). The representative PLN values
shown in the dot plots are: 3.37% (negative), 9.21% (SLC), 3.26% (SLC+LAM1116) and 3.57% (SLC+LAM1-101) (Figure 26 E-H). Summary transformed data
demonstrate the same results (Figure 27). Therefore, a modest increase in
apoptosis was observed for all SLC-treated cells with the LAM1-116 mAb-treated
sample exhibiting the highest response, albeit statistically insignificant.
iv. CD8+ T cell apoptosis at 72 hour post-TCR stimulation
Representative CD8+ T cell dot plots at 72 hour post-stimulation showed a
general decrease in apoptosis with the LAM1-116 mAb-treated sample showing
the biggest decrease (Figure 28). These results were surprising given that the
opposite effect was found at the 36 hour time point, post-TCR stimulation.
Specifically, splenic CD8+ T cells treated with SLC+LAM1-116 mAb showed 5.8%
apoptosis, compared to 6.84% (negative), 7.63% (SLC) and 7.97% (SLC+LAM1101) (Figure 28A-D). The same relative decrease in apoptosis was also observed
in

the representative PLN samples with 28.97% (negative), 24.75% (SLC),

19.59% (SLC+LAM1-116) and 25.83% (SLC+LAM1-101) (Figures 28 E-H).
Variances between transformed samples in the spleen were significant at n=4,
P=0.004

(SLC=68.86±2.4%,

SLC+LAM1-116=53±3.31%

and

SLC+LAM1-

101=71.5±3.06%) and in the PLN at n=4, P=2.15x10-6 (SLC=93±0.55%,
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SLC+LAM1-116=84±0.74% and SLC+LAM1-101=92.69±0.27%) (Figure 29).
These results show that activation through L-selectin results in an anti-apoptotic
effect in CD8+ T cells that is detectable at 72 hours post-TCR stimulation.

v. Correlation between L-selectin and apoptosis levels
Utilizing Pearson’s r, we then subjected all apoptotic values compared to
all frequencies of L-selectin positive cells regardless of tissue origin and cell
subset to a correlation test, coupled with a correlogram (Figure 30). The
frequency of L-selectin positive cells was not correlated to the 72 hour rates of
apoptosis (r=0.11, P=0.47) but interestingly in the 36 hour rates of apoptosis
there was a significant negative correlation (r=-0.40, P=0.0045). Interestingly, the
36 hour time point is when the rates of apoptosis were all increased across all
treatments, with the LAM1-116 mAb treatment eliciting the greatest rate of
apoptosis.
4. Discussion
Unlike the proliferation results described in chapter 2, the apoptosis
results are much less straightforward. At the 72 hour time point, all samples
treated with the LAM1-116 mAb showed a significant decrease in apoptosis,
compared to all other samples (Figure 25 and 29). Interestingly, the lowest level
of apoptosis observed was in the CD8+ splenic T cell subset, contrary to our
tissue origin prediction. We predicted the apoptotic effect would be more
pronounced in the PLN, due to the higher frequency of L-selectin expressing
cells in this tissue. It should be noted that T cells do not constitute the bulk of the
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lymphocyte population in the spleen; rather B cells are the dominant lymphocytes
in this tissue.
Analyzing our correlation data also shows no significant relationship
between frequency of L-selectin positive cells and apoptotic rate at the 72 hour
time point (Figure 30). However, a negative correlation between L-selectin
frequency and apoptosis was detected at the 36 hour time point (Figure 30). This
is in direct opposition to the summary data (Figure 23, 25, 27 and 29). Therefore,
it is highly unlikely that there is any direct relationship between L-selectin
frequency and apoptosis based on the present data. However, there may be a
mechanistic reason behind these findings as discussed below.
At the 36 hour time point, our findings directly contradict our expectations.
Specifically, LAM1-116 mAb treatment tended to induce higher levels of
apoptosis in all samples regardless of tissue origin (Figures 23 and 27). It must
be noted that initial TCR stimulation induced by cross linking CD3 can increase
levels of apoptosis in a phenomenon described as activity induced cell death
(AICD or ACD, 127-129). It should be noted that CD3 mediates initial activation
of T cells and thus exerts its influence at early time points, similar to the 36 hours
post-stimulation apoptosis analysis undertaken in this study. Thus, we can
assume that the latter stages of cell proliferation are no longer mediated by CD3
or its effects are no longer dominant. Despite CD3 activation explaining initial
increases in apoptosis, what explains the decline in apoptosis observed in the 72
hour post-stimulation samples? In light of the mechanism proposed in Chapter 2,
the temporal basis of the initial increase in apoptosis followed by a decrease can
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be explained. As discussed in Chapter 2, a possible mechanism for L-selectin
signaling is through the Ras signaling pathway. We propose that Ras is recruited
via a prototypical Grb2/SOS recruitment to the inner cell membrane, which in turn
was mediated by 14-3-3 binding to the phosphoserine residues in the L-selectin
tail. 14-3-3 has been shown to sequester pro-apoptotic factors in the cytoplasm
through protein-protein interactions. The primary apoptotic factors sequestered
by 14-3-3 includes but is not limited to: BCL-2/XL Associated Death promoter
(130), BCL-2 associated x protein (131) and Forkhead box 01 transcription factor
(FOXO, 132). If we consider the disruption of 14-3-3 interaction with proapoptotic genes, we can certainly see a possible increase in apoptosis when 143-3 protein leaves its pro-apoptotic partner and interacts with the phosphorylated
L-selectin tail. This is reflected in the 36 hour apoptotic rates in the presence of
L-selectin activation. However, what accounts for the 72 hour time point
decrease in apoptosis? Again the L-selectin tail can point us in the right direction.
During L-selectin signaling one of the first molecules that is released from
its interaction with the cytoplasmic tail is CaM. CaM has been shown to be an
anti-apoptotic signal. CaM can counteract apoptosis by several mechanisms
including but not limited to CaM dependent protein kinase 4 (133-134), CaM
dependent kinase 2 (135-136) and via Protein Kinase B (137-138). At the 36
hours post-TCR stimulation time point, it is possible that the apoptotic factors
released from sequestration by the 14-3-3 protein could overcome the antiapoptotic effects of CaM. However, by the 72 hour post-TCR stimulation time
point, it is possible that 14-3-3 together with CaM can exert an anti-apoptotic
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effect that is detectable. This effect may be partly due to the proteolytic
degradation of the L-selectin tail at the later time points. These temporal effects
of 14-3-3 and CaM could explain the differences in the apoptotic rates observed
at the 36 and 72 hours post-TCR stimulation time points. This complexity could
also explain the lack or paradox of correlation between L-selectin activation and
apoptosis at both time points. However, further biochemical analysis involving
14-3-3 and CaM must be undertaken to support the proposed mechanism
outlined above.

+

Figure 22. Representative dot plots of apoptotic CD4 T cells at 36 hours post-TCR stimulation. Cells were isolated from spleen ( A-D) and PLN
(E-H), and stained with 0.25 M of CFSE. Some samples were treated with 10 g/mL of the L-selectin activating mAb, LAM1-116, before
transmigration in the presence of 500 ng/mL of SLC (SLC+LAM1-116, C and G). Other samples were transmigrated to the same concentration of
SLC with no mAb treatment (SLC, Figures B and F) or treated with 10 g/mL of a control mAb, LAM1-101 (SLC+LAM1-101, D and H). Cells that
transmigrated to media alone without mAb treatment are considered negative (A and E). All 4 treatment subsets were subsequently induced to
4
proliferate in the presence of anti-CD3 and anti-CD28 mAbs in a 96 well plate (both mAb at 2g, with 5x10 cells per well). Subsequently, cells
were collected after 36 hours, and the subset (y axis) analyzed for apoptosis (Propidium Iodide positive cells, x axis). Numbers in red indicate cell
percentages per quadrant. Results are representative of 4 independent experiments per tissue.
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Figure 23. Summary data of CD4 T cell apoptosis at 36 hours post-TCR stimulation. Results are from experiments shown in Figure 22. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
Group variances are not statistically significant, with P values of 0.511 and 0.275 for spleen (n=4) and PLN (n=4), respectively. Statistical analysis
was performed using R version 2.15.2. ns indicates not significant.
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Figure 24. Representative dot plots of apoptotic CD4 T cells at 72 hours post-TCR stimulation. Samples were treated as described in Figure 22
and analyzed 72 hours post-TCR stimulation. Numbers in red indicate cell percentages per quadrant. Results are representative of 4 independent
experiments per tissue.
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Figure 25. Summary data of CD4+ T cell apoptosis at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 24. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
In both the spleen and PLN, variances (one-way ANOVA) between treatments was significant, n=4, P=0.007; n=4, P=0.01; respectively. In the
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC
alone, n=4, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=4, P=0.02. In the PLN, the differences between
groups were significant in both cases: n=4, P=0.01; n=4, P=0.02; respectively. Statistical analysis was performed using R version 2.15.2. *
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.
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Figure 26. Representative dot plots of CD8 T cell apoptosis at 36 hours post-TCR stimulation. Cells were treated as described in Figure 22.
Numbers in red indicate cell percentages per quadrant. Results are representative of 5 independent experiments per tissue.
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Figure 27. Summary data of CD8 T cell apoptosis at 36 hours post-TCR stimulation. All samples were treated as described in Figure 22. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
Group variances were not statistically significant, with P values of 0.276 and 0.24 for spleen (n=5) and PLN (n=5), respectively. Statistical analysis
was performed using R version 2.15.2. ns indicates not significant.
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Figure 28. Representative dot plots of apoptotic CD8 T cells at 72 hours post-TCR stimulation. Samples were treated as described in Figure 22
and analyzed for apoptosis 72 hours post-TCR stimulation. Numbers in red indicate cell percentages per quadrant. Results are representative of 4
independent experiments per tissue.
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Figure 29. Summary data of CD8 T cell apoptosis at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 28. All
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100).
-6
In both the spleen and PLN, variances (one-way ANOVA) between treatments was significant, n=4, P=0.004; n=4, P=2.15x10 ; respectively. In
the spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with
SLC alone, n=4, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=4, P=0.005. In the PLN, the differences
-6
-6
between groups were significant in both case : n=4, P=5.5x10 ; n=4, P=9.3x10 ; respectively. Statistical analysis was performed using R version
2.15.2. * indicates PAnova<0.05. ** indicates PTukey HSD<0.05.
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Figure 30. Correlogram of L-selectin positive cell frequency versus 36 and 72 hour apoptosis. Data is from experiments shown in Figures 22-29.
+
+
+
The apoptotic frequency ( x axis) from both CD4 and CD8 T cells were correlated to frequency of L-selectin cells (LAMlevels, y axis) in all cells
from all tissues. Dot plots (A, B and D) and their corresponding best fit line (C, E and F) are shown. Pearson’s correlation is significantly negative
+
between L-selectin cell frequency (LAMlevels, y axis) and decreases in apoptosis (x axis) with n=50, r=-0.40, P=0.0045,at 36 hours (Figures B
and E). All other correlations were not significant. Statistical analysis was performed using R version 2.15.2.
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Chapter 4: Conclusions
The current studies show that L-selectin engagement in conjunction with
the presence of a transmigration signal via CCR7, enhances subsequent TCRinduced proliferation and protects activated T cells from late apoptosis. As
alluded to in the discussions of the previous chapters, we propose a model that
involves the 14-3-3 adaptor protein. Although speculative in nature, 14-3-3
binding can explain the temporal differences observed in proliferation
enhancements and apoptotic protection. It is known that the cytoplasmic tail of Lselectin contains one (for mice) or two (for humans) serine residues that are
phosphorylated by PKC isoforms (84). It is also known that these potential
phosphoresidues are protected by CaM and ERM binding during homeostatic
conditions (101). It must be noted that CaM and 14-3-3 proteins are both helical
in structure, CaM with 7 helices and 14-3-3 with 9 (139-140). We propose that
the phosphoserine residues can attract 14-3-3 binding. This binding can bridge
Grb2/SOS and Ras association. SOS could then exchange the bound nucleotide
of Ras from GDP to GTP, resulting in an activated Ras molecule (113). This
activated Ras molecule could now induce kinase cascades resulting in an
increase in signaling pathways including: the Raf/MEK/ERK (Extracellular SignalRegulated Kinases) pathway, the MEKK/SEK/JNK (Jun N-terminal Kinases)
pathway, a PI3K (Phosphatidylinositol 3-Kinase)/Akt/NF-KappaB (Nuclear
Factor-Kappa B) pathway, in addition to others (141-142). The ultimate purpose
of this signaling collective is to drive T cell activation and proliferation. However,
14-3-3 binding to the phosphorylated L-selectin cytoplasmic domain is not
without a cost. 14-3-3 is known to bind and sequester apoptotic factors in the
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cytoplasm (143); it is likely then that the cost of an increase in proliferation is also
a concomitant increase in apoptosis which we detected at 36 hours post-TCR
stimulation. At the 36 hour time point it is likely that there are two conflicting
signals in terms of apoptosis, the 14-3-3 release of its pro-apoptotic partners and
the release of the CaM from the L-selectin tail, an anti-apoptotic molecule. It is
possible then that at the early time points, the apoptotic signal is greater than the
anti-apoptotic signal. However, once the L-selectin tail has been proteolytically
digested, 14-3-3 returns to the cytoplasm and sequesters the pro-apoptotic
factors again. Furthermore, with CaM no longer able to interact with the Lselectin tail, this molecule can add to the anti-apoptotic environment at 72 hours
post-TCR stimulation. Figure 31 illustrates the model outlined above.
L-selectin’s primary role has always been the homeostatic recirculation of
naïve T cells. However, studies have also shown its ability to serve as a signaling
molecule, improving the immunogenic ability of leukocytes as well as enhancing
adhesion steps downstream from its own. The 17 amino acid cytoplasmic domain
may be an incidental signaling molecule. Through its phosphorylated form, it
likely serves as a signaling scaffold for multiple pathways, in a temporal and
spatial fashion. The usefulness and importance of such signaling ability may be
lost in the in vitro context of this study. Specifically, we need to be aware that the
signaling context of this study is in receptor saturated conditions (i.e., antibody
ligation), conditions that may not be applicable in vivo. However, in less than
saturated conditions, where a minimal repertoire of receptors are engaged, a
scaffolding function may be important, especially in focal adhesions and the
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immunological synapse. Further studies, especially in vivo are required, before
such

functions

may

be

directly

attributable

to

L-selectin.

Figure 31. Proposed mechanism of L-selectin contribution to proliferation and apoptotic protection. In A, L-selectin is dimerized by CaM and ERM
interaction. 14-3-3 sequesters BAD from the mitochondria and SOS and Ras are not associated with each. In B, L-selectin’s interaction with Cam
and ERM is disrupted by ligand binding, the cytoplasmic tail is phosphorylated which recruits 14-3-3. 14-3-3 can now mediate SOS-Ras interaction
which activates Ras resulting in higher levels of proliferation. However, BAD is now free to translocate to the mitochondria resulting in higher levels
of apoptosis. In C, after the initial levels of L-selectin activation has plateaued and the tail is proteolytically digested, CaM can phosphorylate
excess free BAD, resulting in 14-3-3 interaction, sequestering BAD again from the nucleus.
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